Philips has settled trade secrets and copyright claims against a medical imaging company, having already survived accusations of breaching antitrust law.
AbbVie and its exclusive licensee have settled a patent lawsuit against Taro Pharmaceutical over a generic rosacea drug.
Illumina and Roche-owned Ariosa Diagnostics filed a joint stipulation asking the US Supreme Court to dismiss a case concerning the eligibility of Illumina’s DNA testing patents.
Several pharmaceutical organisations have joint-published a five-step plan to help provide more equitable access to COVID-19 vaccines that would avoid waiving IP rights.
The University of California Berkeley has lost a CRISPR patent in Europe in the latest twist in the long-running IP saga over the gene-editing technology.
The US House of Representatives has passed a bill to amend exclusivity laws for drugs on the US Food and Drug Administration’s orphan drugs list.
Takeda subsidiary Baxalta has agreed to drop its fightback against a $173 million award in favour of Bayer after an appeals court upheld a patent infringement win for the German conglomerate.
The Trademark Trial and Appeal Board (TTAB) will start expediting the review and issuance of ex parte appeal decisions related to COVID-19 trademarks.
Roche Group’s subsidiary Spark Therapeutics has filed a complaint against rival gene therapy company Bluebird Bio, accusing it of infringing its ‘Spark’ trademark.
Patenting cannabinoids is an established practice in life sciences, but there are a host of other controlled substances in the field of psychoactives that companies have been rushing to patent.